Analytics, not advice. Rankings and scores describe past performance and are not recommendations.
Uncategorised
Mirae Asset Healthcare Fund - Direct Plan - Growth
Mirae Asset Mutual Fund · Managed by Vrijesh Kasera; Tanmay Mehta
97strong
Latest NAV
₹51.6020
as of 18 Aug 2026
AUM
—
Expense ratio
0.44%
as of 30 Jun 2026
Inception
14 May 2026
FundScore
97/100strong
Rank #36 of 1015 · top 3%
A daily percentile of this fund’s past performance within its SEBI category — analytics, not advice, and not a prediction or recommendation.
Trailing returns
Annualised returns to the latest NAV. Refreshed nightly.
1M
2.80%
3M
7.20%
6M
20.10%
1Y
18.82%
3Y CAGR
23.06%
5Y CAGR
15.90%
Since incep.
22.27%
Fund details
- Fund manager
- Vrijesh Kasera; Tanmay Mehta
- Riskometer
- Very High Risk
- Type
- Open Ended
- Portfolio turnover
- 30%
- Volatility (3Y)
- 15.7%
- Rating (external)
- —
Investment objective
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sectors in India. The Scheme does not guarantee or assure any returns.
NAV history
Zoom and pan · ranges from 1M to since-inception.
Rolling returns
Every 30-day step. The true distribution, not cherry-picked.
Rank history
Percentile within category over the last 2 years.
FundScore components
Pro-only breakdown of consistency, recency, and volatility scores.
Upgrade to Pro to see the raw drivers behind this scheme's FundScore label.
Pro
Market-cap distribution
Large / mid / small / micro-cap split of this fund's equity holdings, from its latest look-through portfolio. Shown as a share of classified equity.
Large cap43.0%
Mid cap33.7%
Small cap23.3%
Stock holdings
Latest portfolio disclosure for this scheme. Snapshot as of 31 Jul 2026.
Sun Pharmaceutical Industries Ltd.
equity
11.06%
Divi's Laboratories Ltd.
equity
8.71%
Torrent Pharmaceuticals Ltd.
equity
7.47%
Apollo Hospitals Enterprise Ltd.
equity
5.94%
Glenmark Pharmaceuticals Ltd.
equity
5.53%
Laurus Labs Ltd.
equity
5.13%
Aurobindo Pharma Ltd.
equity
3.82%
Alkem Laboratories Ltd.
equity
3.56%
Fortis Healthcare Ltd.
equity
3.55%
Krishna Institute of Medical Sciences Ltd.
equity
3.48%
Dr. Reddy's Laboratories Ltd.
equity
3.46%
Lupin Ltd.
equity
3.27%
Onesource Specialty Pharma Ltd.
equity
3.23%
Sai Life Sciences Ltd.
equity
3.17%
Aster DM Quality Care Ltd.
equity
3.14%
IPCA Laboratories Ltd.
equity
3.13%
Cipla Ltd.
equity
3.03%
Eris Lifesciences Ltd.
equity
2.82%
Dr. Lal Path labs Ltd.
equity
2.81%
Max Healthcare Institute Ltd.
equity
2.81%
Gland Pharma Ltd.
equity
2.11%
Biocon Ltd.
equity
2.08%
Mankind Pharma Ltd.
equity
2.04%
Narayana Hrudayalaya Ltd.
equity
1.19%
Anthem Biosciences Ltd.
equity
1.15%
Neogen Chemicals Ltd.
equity
0.61%
Deepak Nitrite Ltd.
equity
0.44%
Mirae Asset Liquid Fund-Direct Plan-Growth
other
0.01%